First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2009-04-02 11:04:30Open Document File Size: 171,64 KBShare Result on FacebookCompanyS-001 NDA APPROVAL Shire Development Inc. / /EventFDA Phase / /FacilityNational Library of Medicine / /IndustryTermtreatment of attention deficit hyperactivity disorder / proposed introductory advertising / drug product / /MedicalConditionattention deficit hyperactivity disorder / /OrganizationFood and Drug Administration Center for Drug Evaluation / Psychiatry Products Office / Food and Drug Administration / DEPARTMENT OF HEALTH / Research Division of Drug Marketing / Advertising / and Communications / Division of Drug Marketing / Advertising / and Communications / /PersonThomas Laughren / Elisa Schneider / Janet Cliatt / / /PositionManager / Regulatory Affairs / Regulatory Project Manager / Director Division / M.D. Director Division / /ProductVyvanse / S-001 / Vyvanse (lisdexamfetamine dimesylate) / HFD-001 / /ProvinceOrStateMaryland / Pennsylvania / /URLhttp /SocialTag |